Does the treatment of rare diseases have a place in tomorrow’s economy in Quebec and Canada?

  Shire, the Irish pharmaceutical company that specializes in the treatment of rare diseases, bought the American group NPS Pharmaceuticals in February 2015 for US$5.2 billion. There have been other financial deals like this recently, always involving amounts in the billions of dollars. For some pharmaceutical companies, developing treatments for...

Continue reading